Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Thrombocythemia, Essential 1Solid Cancers 1Polycythemia Vera 1Neoplasm of Uncertain Malignant Potential 1Hemangiosarcoma 1Carcinoma, Squamous Cell 1

Interventions

Cisplatin 17pembrolizumab 12Radiotherapy 11Nivolumab 7Cetuximab 6Paclitaxel 5fludarabine 4aldesleukin 4Radiation 4Interleukin-2 4Docetaxel 4Cyclophosphamide 4olaparib 3fludarabine phosphate 3Carboplatin 3talimogene laherparepvec 2atezolizumab 2Taxes 2Sorafenib 2Fluorouracil 2Erlotinib Hydrochloride 2Drug Therapy 2Capecitabine 2Bortezomib 2130-nm albumin-bound paclitaxel 2vandetanib 1tozuleristide 1tilsotolimod 1testosterone enanthate 1temoporfin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Squamous Cell × peginterferon alfa-2a × Clear all
NCT05729139 2023-08-09

Cemiplimab/Peg-Interferon-α in Advanced CSCC

Baptist Health South Florida

Phase 1 Withdrawn
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡